Eyevensys
Latest round
- Series B
Last raised
- Aug 2021
Total raised
- $26M
Investors
- 9
About Eyevensys
Founded in 2008 in Paris, France, Eyevensys SAS develops therapies for retinal diseases.Eyevensys SAS specializes in two key products: PST-611 and PST-809. PST-611 targets dry AMD and GA by utilizing a plasmid that expresses human transferrin, crucial for managing retinal iron levels and oxidative stress, while PST-809 is focused on wet AMD, combining anti-VEGF components with decorin to tackle both VEGF-dependent and independent pathways.Eyevensys SAS generates revenue primarily through partnerships with healthcare institutions and licensing agreements for its therapies, PST-611 and PST-809. These products are integrated into patient treatment regimens within ophthalmology, allowing for tailored service delivery and long-term solutions for vision loss caused by retinal diseases. The company is targeting expansion into new markets, particularly in regions with high AMD prevalence, by leveraging partnerships with healthcare providers.
Who invested in Eyevensys
9 investors across 4 rounds
See all investors in Eyevensys
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Eyevensys
Who invested in Eyevensys?
Eyevensys has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Eyevensys raised?
Eyevensys has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Eyevensys last raise money?
Eyevensys's most recent round on record is a Series B, in Aug 2021.
What does Eyevensys do?
Founded in 2008 in Paris, France, Eyevensys SAS develops therapies for retinal diseases.
Where is Eyevensys headquartered?
Eyevensys is headquartered in Paris, France.
Which VCs invest in companies like Eyevensys?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Eyevensys's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Eyevensys? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.